• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转换酶抑制剂的年龄相关性效应:一篇评论

Age-related effects of converting enzyme inhibitors: a commentary.

作者信息

Ball S G

机构信息

Department of Cardiovascular Studies, University of Leeds, England.

出版信息

J Cardiovasc Pharmacol. 1988;12 Suppl 8:S105-8.

PMID:2469890
Abstract

Experience with angiotensin converting enzyme (ACE) inhibitor drugs as with other antihypertensive agents, is limited in the elderly. Nevertheless, they appear effective and well tolerated but without evidence to suggest that they have any special role in the elderly compared to a younger age group. Most are excreted through the kidney and dosage should be reduced to match glomerular function. ACE inhibitors seem likely to be used increasingly in the elderly, especially when more traditional agents are contraindicated because of concomitant disease.

摘要

与其他抗高血压药物一样,老年人使用血管紧张素转换酶(ACE)抑制剂的经验有限。然而,它们似乎有效且耐受性良好,但没有证据表明与年轻人群相比,它们在老年人中有任何特殊作用。大多数通过肾脏排泄,应减少剂量以匹配肾小球功能。ACE抑制剂在老年人中的使用可能会越来越多,尤其是当由于合并症而禁忌使用更传统的药物时。

相似文献

1
Age-related effects of converting enzyme inhibitors: a commentary.转换酶抑制剂的年龄相关性效应:一篇评论
J Cardiovasc Pharmacol. 1988;12 Suppl 8:S105-8.
2
Age-related effects of angiotensin converting enzyme inhibitors.血管紧张素转换酶抑制剂的年龄相关效应。
J Cardiovasc Pharmacol. 1988;12 Suppl 8:S100-4.
3
Clinical use of angiotensin-converting enzyme inhibitors in patients with renal impairment.
Blood Press Suppl. 1994;2:31-4.
4
[Converting-enzyme inhibitors in the treatment of elderly hypertension patients].[转换酶抑制剂在老年高血压患者治疗中的应用]
Wien Med Wochenschr. 1990 Jan 31;140(1-2):30-4.
5
[Angiotensin converting enzyme inhibitors for hypertension].[用于治疗高血压的血管紧张素转换酶抑制剂]
Pol Merkur Lekarski. 1997 Jan;2(7):66-70.
6
ACE inhibitors and strategies for managing hypertension.血管紧张素转换酶抑制剂与高血压管理策略
Postgrad Med J. 1989;65 Suppl 1:S58-60.
7
Impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors.疾病状态对血管紧张素转换酶抑制剂药代动力学和药效学的影响。
J Clin Pharmacol. 2006 Sep;46(9):968-80. doi: 10.1177/0091270006290333.
8
[Captopril and other angiotensin converting enzyme inhibitors in the treatment of hypertension].[卡托普利及其他血管紧张素转换酶抑制剂治疗高血压]
Vnitr Lek. 1995 May;41(5):336-9.
9
Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?肾素-血管紧张素系统抑制对靶器官保护的作用:我们能否做得更好?
Clin Ther. 2007 Sep;29(9):1803-24. doi: 10.1016/j.clinthera.2007.09.019.
10
Renal effects of angiotensin-converting enzyme inhibitors that result in cost savings and improved patient outcomes.血管紧张素转换酶抑制剂的肾脏效应可节省成本并改善患者预后。
Am J Manag Care. 2001 Mar;7(3):283-95.

引用本文的文献

1
Angiotensin converting enzyme inhibitors and moderate hypertension.血管紧张素转换酶抑制剂与中度高血压
Drugs. 1990 Sep;40(3):326-45. doi: 10.2165/00003495-199040030-00002.
2
Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.酮色林。对其药效学和药代动力学特性以及在高血压和外周血管疾病中的治疗潜力的综述。
Drugs. 1990 Dec;40(6):903-49. doi: 10.2165/00003495-199040060-00010.